nystatin vaginal cream / Generic mfg. - LARVOL DELTA

Antifungal de-escalation strategy in ICU patients: clinical success and cost savings (IDWeek 2019) - "Survival rates at day 28 were not statistically significant among the two groups [15/22(68%) vs 11/25(44%), p=0.12]. The budget impact of using de-escalation was greater, producing cost savings of € 3,200 per patient but did not translate into significant clinical and mycological success. Conclusion : Critically ill patients who had received empiric antifungal therapy for documented candidemia and underwent de-escalation from echinocandins or liposomal ambisome B to fungostatin had a potential economic cost-benefit but did not associate with significantly improved clinical success rates."

Clinical • HEOR